Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 14/20 | 0.47 |
| ▸ | PIK3C2G | O75747 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398032 | 0.86 | PIK3CD (0.47) | PIK3CDPIK3CGPI4KBPIK3CAPI4KA | |
| SCHEMBL2398117 | 0.84 | PIK3CD (0.50) | PIK3CDPIK3CGPI4KBPIK3CAPI4KA | |
| SCHEMBL2395910 | 0.81 | MEN1 (0.60) | PIK3CDPIK3CGPIK3CA | |
| SCHEMBL2399934 | 0.80 | MEN1 (0.53) | PIK3CDPIK3CGCA9PIK3CA | |
| SCHEMBL48498 | 0.78 | PIK3CD (0.72) | PIK3CDPIK3CGPI4KBPIK3C2GPIK3CA | |
| SCHEMBL2396335 | 0.76 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CA | |
| SCHEMBL22336563 | 0.76 | PI4KB (0.74) | PIK3CDPIK3CGPI4KBPIK3C2GPIK3CA | |
| SCHEMBL6276205 | 0.76 | MEN1 (0.41) | PIK3CDPIK3CGPI4KBPIK3C2GPIK3CA | |
| SCHEMBL22219021 | 0.76 | CA12 (0.51) | PIK3CDPIK3CGPI4KBPIK3C2GCA12 | |
| SCHEMBL30792284 | 0.75 | PIK3CD (0.58) | PIK3CDPIK3CGPI4KBPIK3C2GPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | PIK3CD 42/4885PIK3CG 49/4885PI4KB 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.